Clinical Trial Update: Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Y-90 radioembolization in combination with durvalumab, tremelimumab, and zanzalintinib for unresectable and locally advanced hepatocell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)
• Y-90 Radioembolization
• Zanzalintinib (Zanzalintinib)

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 2 | Status: NOT_YET_RECRUITING